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25 Abstract
26 Recent studies have shown contradictory associations between calcium levels and health 
27 outcomes. We suspected these conflicting results were the consequence of more general 
28 issues with how biomarkers are analyzed in epidemiological studies, particularly in the 
29 context of aging. To demonstrate the risks of typical analyses, we used three longitudinal 
30 aging cohort studies and their demographic subsets to analyze how calcium levels change 
31 with age and predict risk of mortality and frailty. We show that calcium levels either 
32 increase or decrease with age depending on the population, and positively or negatively 
33 predict frailty depending on the population; both age and frailty results showed substantial 
34 heterogeneity. Mortality analyses revealed few significant associations but were likely 
35 underpowered. Variation in population composition (demographics, diseases, diet, etc.) leads 
36 to contradictory findings in the literature for calcium and likely for other biomarkers. 
37 Epidemiological studies of biomarkers are particularly sensitive to population composition 
38 both because biomarkers generally have non-linear and often non-monotonic relationships 
39 with other key variables, notably age and health outcomes, and because there is strong 
40 interdependence among biomarkers, which are integrated into complex regulatory networks. 
41 Consequently, most biomarkers have multiple physiological roles and are implicated in 
42 multiple pathologies. We argue that epidemiological studies of aging using biomarkers must 
43 account for these factors, and suggest methods to do this.
44
45 Key Words: Aging biomarkers, population composition, physiological complexity, calcium, 
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48
49 Introduction
50 Clinical and epidemiological studies of biomarkers during aging often characterize 
51 associations between a single marker and either age or relevant health outcomes (Glei and 
52 others 2011; Liu and others 2015; Loeffen and others 2015; Schottker and others 2015; 
53 Schram and others 2007). However, we and others have previously observed that many 
54 standard clinical biomarkers have surprisingly variable associations with age in different 
55 populations (Cohen and others 2015b; Martin-Ruiz and von Zglinicki 2014; Sebastiani and 
56 others 2016), and we were worried that many biomarker findings in the literature might be 
57 poorly generalizable. 
58 Individual biomarkers do not necessarily change linearly with, or independently of, other 
59 aspects of physiology, but rather are integrated into physiological regulatory networks that 
60 can exhibit properties of formally complex systems (Cohen 2016; Cohen and others 2012). 
61 Accordingly, many biomarkers have multiple physiological determinants and roles and can 
62 fluctuate for diverse physiological and pathophysiological reasons (see below for details, 
63 taking calcium as an example). Biomarkers are thus rarely a direct window into the 
64 underlying physiological processes of interest, but are rather proxies, the efficacy of which 
65 can depend heavily on other biomarkers, disease state, and demographics. 
66 Another consequence of complex physiological integration is that changes with age are 
67 generally non-linear and usually non-monotonic as well (i.e., showing periods of both 
68 increase and decrease). For example, a long-term study of seven biomarkers in the 
69 Framingham Heart Study found that six showed non-monotonic changes across the adult life 
70 course (Yashin and others 2010). Thus, since disease prevalence and physiological traits can 
71 vary greatly across populations, population composition should have a strong role in 
72 determining biomarker-age associations in any given study. For example, if a biomarker 
73 happens to be elevated in diabetics, observed changes in the biomarker with age may depend 
74 strongly on the prevalence and severity of diabetes in the population, the age structure of 
75 diabetes incidence, and impacts of diabetes on other outcomes except aging and mortality, 
76 all of which can be quite variable but are unrelated to the fundamental question of how the 
77 biomarker may or may not predict aging. Such effects are likely to be present even in 
78 longitudinal studies, where biomarkers may evolve differently with age and have different 
79 impacts in specific subpopulations.
80 This article attempts to address this challenge by combining aspects of a review and 
81 aspects of an empirical study. We first conduct analyses of how calcium associates with age, 
82 mortality, and clinical frailty in three different cohort studies of aging and their demographic 
83 subsets. We demonstrate that results are highly heterogeneous across populations. 
84 Obviously, calcium is but a single example, so our discussion then goes well beyond our 
85 particular findings to consider the theoretical basis of why biomarker studies should generate 
86 such unstable results, and how to address the problem. We propose a number of concrete 
87 methods to help mitigate the problem.
88
89 The example of calcium
90 Within the aging context, calcium has not particularly been proposed as a single biomarker 
91 of aging, and is generally analyzed rather as one among many markers in a panel (Martin-
92 Ruiz and others 2011; Szewieczek and others 2015). Nevertheless, calcium levels are 
93 increasingly believed to be associated with risk of mortality and morbidity. While many 
94 studies with middle-aged adults report associations between high calcium levels and 
95 increased risk of mortality (Larsson and others 2010; Reid and others 2016), findings in 
96 oldest adults tend to show reduced adverse outcomes for higher calcium levels, perhaps 
97 reflecting the concomitant higher albumin levels within this group (Szewieczek and others 
98 2015). Non-linear associations have also been reported (Larsson and others 2010), notably 
99 U- or J-shaped curves (Durup and others 2012; Lu and others 2016). 
100 Calcium is involved in many crucial physiological functions, notably neuronal 
101 transmission, immune cell stimulation, apoptosis, bone health maintenance, muscle 
102 contraction – including the heart – and blood coagulation (Shaker and Deftos 2000). In the 
103 blood, its ionized form is believed to be the more closely regulated one, and accounts for 
104 approximately 50% of total serum calcium, the rest being bound to serum proteins, mainly 
105 albumin (Brown 2001). Abnormalities in albumin and globulins may affect total serum 
106 calcium levels, but the ionized level should remain unchanged for a given pH (Payne and 
107 others 1973). Hypercalcaemia has various causes, notably cancer and hyperparathyroidism, 
108 whereas hypocalcaemia is generally due to hypoparathyroidism or chronic renal failure 
109 (Parfitt 1979). Many undetected pathological conditions related to age may influence 
110 calcium homeostasis and as such remain undiagnosed for long-time.
111 The relationship between calcium and generalized risks of adverse outcomes during 
112 aging thus appears to be a complex one. First, both high and low levels might have 
113 detrimental effects on physiological homeostasis. Thus, population composition, most 
114 notably age, might strongly affect possible associations between calcium and risk of health 
115 outcomes. For instance, while high calcium levels at mid-life may be linked to adverse 
116 outcomes, the inverse relationship might take place at older ages. To demonstrate this idea, 
117 we looked at age-related changes in calcium, and its potential association with frailty and 
118 mortality, across three longitudinal cohort studies of aging. Analyses were repeated in 
119 different cohort subsets (sex, race, and age) to assess the effect of population composition on 
120 potential associations. Our objective was to demonstrate the limits of such single-biomarker 
121 epidemiology in the context of the complex process of aging.
122 Detailed Methods are provided in the online Appendix; here we note principally that we 
123 have taken care to reproduce the methods most common in the literature. For example, it is 
124 common to use measures of calcium adjusted for albumin levels, and we thus used both a 
125 raw and albumin-adjusted version. There are two principal exceptions where we opted for 
126 methods more sophisticated than are standard. First, many analyses use tertiles or other 
127 quantiles, and we disfavour this approach because it causes a loss of statistical power and 
128 can cause important biases and inflation of Type-I error without any important justification 
129 (Barnwell‐Ménard and others 2015). We thus always consider calcium as a continuous 
130 variable. Second, age was sometimes controlled using a cubic spline, a more sophisticated 
131 approach than age categories or age as a linear variable. 
132 Table 1. Characteristics of study populations (at first visit).
 
Characteristic 
InCHIANTI WHAS I WHAS II BLSA
Characteristic n = 1310 n = 796 n = 430 n = 1290
Age 
       Mean ± SD 68.3 ± 15.4 78.5 ± 7.9 74.7 ± 2.9 64.9 ± 14.0
       Range (min – max) 21.3 – 98.4 65.8 – 100.3 70.2 – 82.5 26.4 – 99.7
Female (%) 727 (55.5) 796 (100.0) 430 (100.0) 636 (49.3)
Race (white, %) 1310 (100.0) 570 (71.6) 348 (80.9) 830 (64.3)
Deaths, number (%) 366 (27.9) 238 (29.9) 173 (40.2) 109 (8.4)
Frailty criteria, number 
            0 (%) 501 (38.2) 81 (10.2) 262(60.9) ─
            1 (%) 255 (19.5) 170 (21.4) 126 (29.3) ─
            2 (%) 128 (9.8) 217 (27.3) 30 (7.0) ─
            3 (%) 59 (4.5) 121 (15.2) 10 (2.3) ─
            4 (%) 33 (2.5) 65 (8.2) 1 (0.2) ─
            5 (%) 10 (0.8) 31 (3.9) 1 (0.2) ─
Ca (mmol/L), mean ± SD 2.36 ± 0.11 2.32 ± 0.11 2.38 ± 0.10 2.30 ± 0.11
Alb-adj ca (mmol/L), mean ± SD 2.31 ± 0.11 2.32 ± 0.11 2.32 ± 0.11 2.30 ± 0.10
133
134 Findings on calcium
135 Association of calcium with age 
136 First, we looked at the association between calcium and age through correlation analyses in 
137 three longitudinal cohort studies of community dwelling older adults (Table 1, see online 
138 Appendix for details), as might be obtained in many cross-sectional studies. As shown in 
139 Table 2, calcium is consistently negatively correlated with age, except for WHAS I (nearly 
140 significant) and WHAS II; however albumin-adjusted calcium (alb-adj ca) shows unstable 
141 results (see Table A.1 for other versions). Alb-adj ca is clearly positively correlated with age 
142 in the InCHIANTI cohort, but not in the other two data sets. Calcium is correlated with 
143 albumin in all three cohorts (0.33   r  0.44, all p<0.001). Calcium and alb-adj ca also 
144 correlate strongly (0.78   r  0.87, all p < 0.001). Surprisingly, alb-adj ca is not much more 
145 correlated with ionized calcium than the unadjusted measure (r = 0.45 compared to r = 0.43) 
146 and thus might not serve as a good proxy for ionized calcium (Fig. A.1).
147
148 Table 2. Correlation coefficients between age and calcium level at first visit.
Calcium Alb-adj ca
Dataset n r p r p
InCHIANTI 1305 -0.073 0.008 0.129 <0.001
WHAS 1189 -0.115 <0.001 -0.029 0.32
WHAS I 766 -0.063 0.08 -0.017 0.64
WHAS II 423 -0.029 0.55 -0.030 0.54
BLSA 1242 -0.126 <0.001 0.036 0.21
All 3736 -0.092 <0.001 0.024 0.14
149 Unadjusted calcium and albumin-adjusted calcium (alb-adj ca) variables were centered at 
150 zero and divided by their standard deviation such that mean was 0 and standard deviation 1. 
151 Significant correlation coefficients are indicated in bold.
152
153
154 Figure 1. Calcium trajectory with age. Changes with age are shown for unadjusted calcium (left panel) and albumin-adj ca (right 
155 panel) variables. Trajectories were estimated using Bayesian mixed models with age as a cubic spline (with 5 knots for InCHIANTI and 
156 BLSA, and 4 knots for WHAS, see Appendix for details) for three longitudinal cohorts, as indicated with different colors. Analyses for 
157 WHAS were performed either combining WHAS I and WHAS II (solid lines), or with either one (dashed lines for WHAS I and dotted 
158 lines for WHAS II). Age started at 66 for WHAS, while InCHIANTI and BLSA had a small fraction of younger subjects.
159  
160 Figure 2. Yearly changes in calcium with age. Trajectories for unadjusted calcium (left panel) and albumin-adj ca (right panel) 
161 variables were estimated using Bayesian linear mixed models (see Appendix for details). Slopes (points) obtained are plotted with their 
162 95% confidence intervals (CIs; segments). Different colors indicate different datasets and text on the right describe the cohort subset on 
163 which the analysis was performed. Analyses for WHAS were performed either combining WHAS I and WHAS II (solid lines), or with 
164 either one (dashed lines for WHAS I and dotted lines for WHAS II). Result for heterogeneity test are also indicated. Significant results 
165 are plotted in bold, with asterisks indicating the significance level (***, p < 0.001; **, p < 0.01; *, p < 0.05).
166
167 Longitudinal changes in calcium levels with age varied markedly across populations 
168 and sub-populations. Across full datasets, alb-adj ca always increases up to 80 years or so, 
169 but diverges across datasets after this age (Fig. 1). In contrast, unadjusted calcium shows 
170 much more variation across populations. These findings are sometimes but not always in 
171 agreement with the correlations based on a cross-sectional approach (Table 2). Using finer-
172 scale sub-populations (Fig. 2), both unadjusted calcium and alb-adj ca can increase or 
173 decrease significantly with age depending on the population, and heterogeneity across 
174 analyses is substantial and highly significant (Table A.2). Calcium slopes (i.e. mean yearly 
175 changes in SDs) varied greatly across these analyses, ranging from -0.02 to +0.08 SDs/year 
176 (Fig. 2). Calcium trajectories also varied substantially according to sex and age group within 
177 each cohort (Figs A.2-A.5). Analysis of calcium trajectories with age in a merged dataset 
178 revealed significant interactions between dataset and slope (Table A.3). Sex also influenced 
179 calcium changes with age for unadjusted calcium, but not the alb-adj ca, with women 
180 showing steeper increases in calcium with age than men when considering all three datasets 
181 ( = 0.008, p < 0.001).
182
183 Association with mortality and frailty
184 Our mortality analyses appear to be underpowered, failing to reach normal significance 
185 thresholds even when effect sizes were large (ranging from 0.88 to 1.27, see Fig. 3). For the 
186 oldest subjects (> 80 yrs), we note a lower mortality risk due to unadjusted calcium in the 
187 InCHIANTI dataset, standing in contrast to previous findings in older populations (Martin-
188 Ruiz and others 2011; Szewieczek and others 2015). Nonetheless, meta-regression of effect 
189 sizes shows that the associations between mortality and calcium do differ across datasets, 
190 even when these associations are not themselves significant: using BLSA led to stronger 
191 effects compared to WHAS I ( = 0.14, p = 0.04) and to InCHIANTI ( = 0.13, p = 0.04), an 
192 effect that failed to reach significance for WHAS II ( = 0.10, p = 0.13). Using alb-adj ca 
193 compared to unadjusted calcium led to higher effect sizes ( =0.13, p = 0.02).
194 Frailty was sometimes associated with calcium levels, but in opposite directions for 
195 unadjusted calcium and alb-adj ca: more frailty criteria were significantly associated with 
196 lower levels of unadjusted calcium, but with higher levels of alb-adj ca in WHAS I and 
197 WHAS II (Fig. 4). However, there was also substantial heterogeneity of these results for 
198 unadjusted calcium, and most results were not significant. Negative associations between 
199 calcium and frailty were more present in WHAS (meta-regression  = -0.05, p = 0.06 and  
200 = -0.07, p = 0.005, respectively for WHAS I and WHAS II) than in InCHIANTI. Type of 
201 calcium measurement also significantly affected the effect size ( = 0.07, p < 0.001, for 
202 considering alb-adj ca compared to unadjusted calcium). 
203  
204 Figure 3. Relationships between calcium and mortality. Estimated hazard ratios (points) together with 95% confidence intervals 
205 (CIs; segments) are plotted for unadjusted calcium (left panel) and albumin-adj ca (right panel) variables, based on counting process 
206 Cox proportional hazards models. See Fig. 2 for further explanations.
207  
208 Figure 4. Relationships between calcium and frailty. Poisson regression models were performed on the number of Fried’s frailty 
209 criteria (Fried and others 2001) for unadjusted calcium (left panel) and albumin-adj ca (right panel) variables, adjusting for age with a 
210 cubic spline. Estimations (points) together with 95% confidence intervals (CIs; segments) are plotted. Longitudinal analyses are shown 
211 on the top panels (for WHAS only) and cross-sectional analyses (using the number of frailty criteria at first visit only) are presented on 
212 the lower panels. See Fig. 2 for further explanations.
213
214 Discussion 
215 Our analyses demonstrate the challenges in using a single biomarker in an 
216 epidemiological study based on a single population. Using the example of calcium, a 
217 biomarker appearing frequently in recent epidemiological studies (Larsson and others 
218 2010; Lu and others 2016; Reid and others 2016), we show that we can detect effects 
219 differing not just in magnitude but direction depending on the population studied and 
220 variable definition. For example, using unadjusted calcium in the whole WHAS data set, 
221 we could have published an article showing that calcium levels increase with age, are 
222 negatively associated with frailty, and unassociated with mortality. However, this 
223 conclusion would not have generalized or yielded any important insight: not only is it not 
224 replicated across datasets, it is not even replicated within WHAS subsets by age and race. 
225 Of course, for the reasons outlined in the Introduction, it would be naïve to 
226 hypothesize a general relationship between calcium and age, mortality, and/or frailty. We 
227 should expect high levels and low levels to arise through different types of underlying 
228 pathology (Parfitt 1979), and to have different consequences for individual health in 
229 different physiological contexts (Szewieczek and others 2015). Because these pathologies 
230 and contexts vary across age groups and populations, population composition can easily 
231 become the primary driver of the results. Our principal objective here is thus not to 
232 illuminate calcium epidemiology during aging, and accordingly our study has a number 
233 of clear limitations in that context. First, we do not consider (nor generally have access 
234 to) sufficient data on dietary consumption or supplements. Second, kidney disease can be 
235 a major factor (Parfitt 1979), but we had insufficient data to perform such analyses. 
236 Third, we did not target specific subpopulations. For example, calcium might conceivably 
237 be a useful biomarker for the efficacy of certain medications to treat osteoporosis, and its 
238 use as a single biomarker in that context might be appropriate.
239 While our principal conclusion concerns biomarkers in aging research generally, 
240 calcium is not representative of all such biomarkers. Some, such as telomere length, 
241 might be markers of the aging process itself, though evidence is mixed (Sanders and 
242 Newman 2013) and hope for a single silver-bullet biomarker of aging is dimming with 
243 increasing realization that aging is a multi-factorial, complex phenomenon (Cohen 2016; 
244 Kirkwood 2005), and that many biomarkers of aging correlate only weakly with each 
245 other (Sanders and others 2014). Others, such as hepcidin, may be indicators of very 
246 specific aspects of physiological functioning or disease states (Nemeth and others 2003). 
247 Calcium is a problematic biomarker because it plays multiple roles and thus can be 
248 implicated in multiple pathologies; its levels need to be considered in light of multiple 
249 other markers (minimally vitamin D, parathyroid hormone, and albumin, Bushinsky and 
250 Monk 1998). Nonetheless, most common clinical biomarkers play multiple roles or 
251 present similar levels of complexity for interpretation, among them cholesterol, albumin, 
252 C-reactive protein (CRP), insulin-like growth factor (IGF-1), haemoglobin, uric acid, and 
253 glucose. These common but challenging markers are increasingly the focus in aging 
254 studies (Beekman and others 2016; Martin-Ruiz and others 2011; Mitnitski and others 
255 2015). A final class of aging biomarkers increasingly thought to be important (but not 
256 always available) are dynamic biomarkers that measure a change in response to a 
257 challenge or stimulus (Kalyani and others 2012; Varadhan and others 2008). 
258
259 Risks of one-at-a-time biomarker analyses
260 These caveats on the use of biomarkers may seem obvious, but they are rarely 
261 incorporated into study design and present a number of specific risks, namely:
262 1. Identification of a biomarker that is conditionally associated with an outcome 
263 despite lack of a clear causal role. For example, CRP is thought to be a marker of 
264 inflamm-aging and heart disease risk; however, it is very high in the Tsimane hunter-
265 gatherers despite an absence of heart disease in this population (Gurven and others 
266 2009). This paradox is due to the multiple roles and associations CRP has with 
267 different aspects of the inflammatory response triggered under different conditions 
268 (Bandeen-Roche and others 2009). Indeed, despite its popularity, CRP is far from the 
269 best marker of inflamm-aging, and multivariate indices perform better than 
270 univariate ones (Cohen and others in press). This problem cannot be avoided by 
271 simple control for other biomarkers in regression models; the complex systems 
272 dynamics and feedback effects among the markers break fundamental assumptions of 
273 such approaches.
274 2. Identification of associations that are not generalizable, as would have happened 
275 had we attempted to publish our calcium findings based only on one of our datasets. 
276 While this risk is present for any study (“external validity”), it is particularly acute 
277 for biomarker studies given the physiological complexity and the history of 
278 conflicting findings.
279 3. Misidentification of “aging biomarkers.” Many biomarkers are thought to change 
280 with age and are accordingly used in analyses to understand the aging process. Often, 
281 a cross-sectional correlation with age is used to determine a set of aging biomarkers 
282 for a more complex analysis (Levine 2013). However, in many cases these age-
283 related changes are either not reproduced in longitudinal analyses (as is the case 
284 here) or are not reproduced across datasets (also true here and in our previous 
285 analyses (Cohen and others 2015b)). For example, both the Pace of Aging (Belsky 
286 and others 2015) and the Klemera-Doubal biological age algorithm (Klemera and 
287 Doubal 2006; Levine 2013) assume linear change in biomarkers with age, and 
288 identify sets of biomarkers based on detected age associations. While both work well 
289 in young cohorts where the changes are closer to linear, non-monotonicity presents 
290 major challenges for implementation in older cohorts (D. Belsky, pers. comm.).
291 4. Perpetuation of a simplified model of physiology and epidemiology. There is no 
292 controversy surrounding either the complex physiological interdependence of many 
293 biomarkers (Cohen 2016; Cohen and others 2012), nor the challenges of considering 
294 population composition in epidemiological studies. Nonetheless, much of the 
295 literature continues to ignore one or both of these factors, generating not just 
296 ungeneralizable results but perpetuating a simplified worldview across generations of 
297 researchers.
298 5. Variation in population composition (demographics, diseases, diet, etc.) leads to 
299 contradictory findings in the literature for calcium and likely for other biomarkers. 
300 Epidemiological studies of biomarkers are particularly sensitive to population 
301 composition both because biomarkers generally have non-linear and often non-
302 monotonic relationships with other key variables, notably age and outcomes, and 
303 because there is strong interdependence among biomarkers, which are integrated into 
304 complex regulatory networks. Consequently, most biomarkers have multiple 
305 physiological roles and are implicated in multiple pathologies.
306
307 Potential solutions
308 We suggest that epidemiological studies using biomarkers, particularly in the context of 
309 aging, must consider three factors: (1) population composition; (2) non-linear and often 
310 non-monotonic relationships between biomarkers and other key variables; and (3) 
311 interdependence among biomarkers due to their integration into complex regulatory 
312 networks. The first factor is often important because of the second and/or the third, but in 
313 practical terms each can be considered as a separate methodological challenge. Each 
314 factor alone is a major challenge, and proper incorporation of all three simultaneously 
315 may seem daunting. Nonetheless, we are convinced it is both possible and essential to 
316 make progress in the field despite these challenges. Here are several suggestions.
317 First, problems related to population composition can be addressed by replication, 
318 both across datasets and within data subsets as shown here. Emphasis should be put on 
319 results that are robust across populations, or where there is a clear explanation for 
320 heterogeneous results. The increasing availability of data from diverse cohorts (Erten-
321 Lyons and others 2012) implies that it should rarely be acceptable to publish analyses 
322 based on a single cohort without independent replication. This is particularly true for 
323 biomarker analyses where there is a high risk of non-replicability. Beyond replication, it 
324 is important to consider what physiological processes or diseases might be linked to the 
325 biomarker in question and how these might vary across populations, particularly when 
326 these processes/diseases are not the focus of the study.
327 Second, multiple methods exist to incorporate non-linearity into analyses, ranging 
328 from a simple quadratic term to generalized additive models to cubic splines; indeed, in 
329 the case of calcium, several studies have used such methods, demonstrating their 
330 importance (Durup and others 2012; Lu and others 2016). Often, optimal biomarker 
331 values are intermediate rather than very high or very low, a reflection of the need to 
332 maintain homeostasis in a complex system (Cohen 2016), and may also be related to the 
333 principle of hormesis (Rattan 2008). This generally produces a non-monotonic 
334 association with the outcome (e.g. U- or J-shaped). In a multivariate context, statistical 
335 distance approaches account for this (Cohen and others 2015a); in a univariate context, 
336 extreme high and low quantiles or absolute values of standard-normal-transformed 
337 variables may be used (Martin-Ruiz and others 2011; Seplaki and others 2005).
338 Third, multiple solutions exist to tackle physiological complexity. Biomarker 
339 dynamics can be evaluated using a stimulus-response paradigm (Varadhan and others 
340 2008). Multivariate biomarker analyses provide promising solutions to the problem of 
341 physiological interdependence (Arbeev and others 2016). Both the Pace of Aging (Belsky 
342 and others 2015) and Klemera-Doubal biological age (Levine 2013) have produced 
343 impressive results despite the above-mentioned caveat with the linearity assumption, 
344 likely because errors related to individual markers wash out when enough markers are 
345 included. Homeostatic dysregulation, as measured via statistical distance, is also a 
346 promising method that does not rely on assumptions of linearity or associations with age 
347 (Cohen and others 2015a). Use of such integrative approaches does not necessarily solve 
348 all questions of population composition (Cohen and others 2016), but can at least avoid 
349 some of the problems of interdependence among markers. 
350 We emphasize that there is no single recipe for how to deal with these challenges, and 
351 not every study will be able to deal with them perfectly. Rather, the point is to consider 
352 them both in study design (e.g. longitudinal cohort studies designed to permit analysis of 
353 multisystem dynamics) and in interpretation. There may be cases where a single 
354 biomarker is linearly related with health outcomes in a stable fashion across populations, 
355 but there is every reason to expect such cases to be few and far between, particularly 
356 when the outcomes are the generalized health conditions common in aging studies 
357 (mortality, frailty, disability, quality of life, physical functioning, cognitive decline, etc.). 
358 The burden should be shifted to authors to prove generalizability and validity, rather than 
359 to suppose them in the absence of evidence, by favouring the design of studies integrating 
360 the above outlined criteria. 
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Material and methods
Data sets
We used data from three longitudinal cohort studies of community dwelling older adults, although two 
contain a small proportion of younger individuals (see Table 1 for details). Invecchiare in Chianti 
(InCHIANTI) is a prospective population-based study of 1156 adults aged 65–102 and 299 aged 20–
64, randomly selected using multistage stratified sampling from two towns in Tuscany, Italy (Ferrucci 
and others 2000). The Women’s Health and Aging Study (WHAS) is a population-based prospective 
study of community-dwelling women drawn from eastern Baltimore City and Baltimore County, 
originally consisting of two separate studies: WHAS I, which includes 1002 women aged 65+ among 
the 1/3 most disabled in the population (Fried and others 1995), and WHAS II, which includes 436 
women aged 70–79 among the 2/3 least disabled (Guralnik 1995). The Baltimore Longitudinal Study 
of Aging (BLSA), one of the world's longest studies of aging in humans, is composed of community-
dwelling adults in the Baltimore and Washington DC areas aged 21–96 (Shock 1984). A 2003 re-
design of methodology was tailored to improve the inference for systems-level questions (Ferrucci 
2009). Although the data used in these analyses cannot be freely shared due to confidentiality 
constraints related to human medical data, they are all available to researchers submitting an 
appropriate research proposal: InCHIANTI at http://www.inchiantistudy.net/obtain_data.html, WHAS 
at https://jhpeppercenter.jhmi.edu/ec_proposal/login.aspx, and BLSA at 
http://www.blsa.nih.gov/researchers. Analyses included 1310 individuals for InCHIANTI, 796 for 
WHAS I, 430 for WHAS II, and 1290 for BLSA, based on calcium variable availability.
All aspects of dataset collection were approved by the ethics committees at the institutions 
responsible for data collection, or by the National Institute of Environmental Health Services Internal 
Review Board for BLSA, and this secondary analysis was approved by the ethics committee (Comité 
d’éthique de la recherche en santé chez l’humain) at the Centre de recherche clinique du CHUS, 
project # 14-059. Participants signed informed consent for data collection and analysis. 
Data analysis
Calcium values were normally distributed in all data sets. Calcium was quantified with or without 
adjustment for albumin (Goltzman 2005): 
Adjusted calcium (mmol/L) = Total calcium (mmol/L) + 0.02 [40 - Albumin (g/L)] (1)
Both versions were then centered at zero by subtracting the mean and scaled to have standard 
deviation (SD) =1 by dividing by SD. We also used absolute values of the above metrics to quantify 
deviation from the mean. Ionized calcium was only available for 296 individuals of the BLSA dataset, 
hence analyses with this variable did not have sufficient statistical power and are thus not presented, 
except to compare to the albumin-adjusted measure (see Fig. A.1).
We used subsets of each cohort to assess the association of calcium and age in different 
population groups: sex, age (<65 years, 65-80 years, and 80+ years), and race (white or black), as 
available for each cohort. Initially, we performed analyses in a small subset of subjects from 
InCHIANTI that had kidney disease, but due to its small number (n = 128), analyses lacked statistical 
power and we had to exclude them. Each analysis was repeated for both calcium variables and all 
cohort subsets. All analyses were performed in R v3.2.2. All code is available at Open Science 
Framework (https://osf.io/wxhc4). 
Association of calcium with age 
First, we assessed cross-sectional associations between calcium and age using Pearson correlations 
(cor.test function), applied only to each individual’s first visit with complete calcium measures. 
Second, to measure longitudinal individual changes, trajectories of calcium with age were estimated 
using Bayesian mixed models implemented in R using the MCMCglmm package, with uninformative 
priors (Hadfield 2010). Burn-in, thinning, and number of iterations were adjusted to arrive at an 
MCMC sample of 1000 retained iterations with minimized auto-correlations in Markov chain samples 
(<0.1) after model convergence (10,100 iterations and burn-in at 100). Initial models used either a 
cubic spline of age or a quadratic function, but the quadratic term was rarely significant (data not 
shown) and were thus excluded from models. Final models included individual-level random 
intercepts and age at each visit, but not individual slopes. We modeled age in two ways: 1) with a 
cubic spline (bs function (fda package), using four knots in WHAS, five knots in InCHIANTI and 
BLSA (due to their larger age range, see Table 1), and three knots for age group subsets; or 2) linearly 
to estimate individual slopes.
Association with mortality and frailty
To analyze the relationship between calcium and mortality, we performed Cox proportional hazards 
regression models (coxph function, survival package). We used calcium values and age at first 
visit, with censoring at age of last contact or death, using a counting process formulation.
We used the number of frailty criteria (between 0 and 5), according to Fried’s phenotype 
definition (Fried and others 2001), which are: 1) unintentional weight loss, 2) fatigue, 3) reduced grip 
strength, 4) reduced physical activity, and 5) low gait speed. Fulfilling three or more of these criteria 
indicates clinical frailty. We used the number of frailty criteria, rather than frailty state in order to 
maximize statistical power; however, similar results are obtained using a dichotomous frail-non-frail 
outcome (data not shown). We did not have frailty measures for BLSA, only at baseline for 
InCHIANTI, but at all visits for WHAS. The association between the number of frailty criteria and 
calcium was assessed using Poisson regression with the glmer function (lme4 package), either 
considering only the first visit or all visits for WHAS. Age cubic spline was included in models as a 
covariate as described earlier. Since data were available longitudinally for WHAS, models including 
subject-level random intercepts were also performed. As Poisson regression may be a questionable 
choice to model the number of frailty criteria, we compared results to models based on ordered 
logistic regression (polr function from the MASS package). Similar results were obtained with both 
models (see Fig. A.10). In our regression models, we also tested an interaction term between the 
calcium variable and age, but chose to exclude it in final analyses since it was generally far from 
significant and often prevented model convergence.
Linear regressions on effect sizes
In order to assess the sensitivity of analyses to the choice of calcium variable and population 
composition, we performed linear regressions (lm function) on the effect sizes obtained with the 
previous analyses (the dependent variable). Models included a dummy variable indicating the type of 
calcium variable (unadjusted calcium = 0; alb-adj ca = 1), as well as age, sex, and dataset used as 
covariates. We also ran Bayesian mixed models (MCMCglmm function) on the full combined dataset to 
look at the effect of dataset and sex on calcium changes with age, including individual slopes as a 
random effect. The crucial term in these models was an interaction between age and dataset or sex, 
which were included in separate models. Finally, we calculated the heterogeneity (Q) among the 
different results using the rma.uni function (metaphor package). Heterogeneity analyses were 
stratified by outcome (age, mortality, frailty). Results were similar with and without stratification by 
longitudinality for frailty (see Table A.2 and Figs 4 and A.9).
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Supplementary Tables
Table A.1. Correlation coefficients between age and calcium level at first visit for absolute 
values. 
|Calcium| |Alb-adj ca|
Dataset n r p r p
InCHIANTI 1305 0.002 0.95 0.073 0.008
WHAS 1189 0.059 0.04 0.055 0.06
WHAS I 766 0.041 0.26 0.029 0.43
WHAS II 423 0.074 0.13 0.067 0.17
BLSA 1242 0.050 0.08 0.010 0.73
All 3736 0.013 0.44 0.039 0.02
Table A.2. Heterogeneity of results obtained with different population compositions for 
associations between calcium and age, mortality, and frailty (see Figs 2-4 and A.7-A.9).
Yearly change Mortality Frailty
Variable Q df p Q df p Q df p
Calcium 206.1 28 <0.001 17.0 25 0.88 66.5 34 0.001
|Calcium| 97.2 28 <0.001 8.3 25 1.00 37.9 34 0.30
Alb-adj ca 430.7 28 <0.001 18.1 25 0.84 37.1 34 0.33
|Alb-adj ca| 89.9 28 <0.001 6.3 25 1.00 31.9 34 0.57
Table A.3. Effect of data set used on slope of calcium with age (compared to InCHIANTI).
WHAS WHAS I WHAS II BLSA
Variable β p β p β p β p
Ca 0.010 < 0.001 0.003 0.46 0.027 < 0.001 0.009 < 0.001
|Ca| 0.007 < 0.001 0.002 0.48 0.016 < 0.001 0.001 0.29
Alb-adj ca 0.016 < 0.001 -0.001 0.69 0.047 < 0.001 0.004 0.07
|Alb-adj ca| 0.005 0.02 -0.002 0.51 0.017 < 0.001 0.001 0.47
Supplementary Figures
Figure A.1. Correlations among different versions of calcium measures. Correlations were calculated with 296 individuals from 
the BLSA cohort. Ellipses above the diagonal indicate correlations visually: blue when positive, red when negative, and darker and 
narrower when stronger. Correlation coefficients are shown below the diagonal. | Ca |, absolute calcium values; Alb-adj Ca, albumin-
adjusted calcium values; | Alb-adj Ca |, absolute albumin-adjusted calcium values.
 
Figure A.2. Calcium trajectories with age according to sex. Yearly change in calcium (left panel) and albumin-adjusted calcium 
(alb-adj. ca; right panel) are plotted as a function of age. Trajectories were estimated using Bayesian mixed models with age as a 
cubic spline (with 5 knots for InCHIANTI and BLSA, and 4 knots for WHAS) for three longitudinal cohorts (as indicated with 
different colors), for males (solid lines) or females (dashed lines). WHAS contains only women and age started at 66, while 
InCHIANTI and BLSA had a small fraction of younger patients and both sexes.
Figure A.3. Absolute calcium trajectories with age according to sex. Yearly change in absolute calcium (|calcium|; left panel) and 
absolute albumin-adjusted calcium (|alb-adj. ca|; right panel) are plotted as a function of age. Absolute values indicate deviation from 
the mean, and thus dysregulation irrespective of direction. Trajectories were estimated using Bayesian mixed models with age as a 
cubic spline (with 5 knots for InCHIANTI and BLSA, and 4 knots for WHAS) for three longitudinal cohorts (as indicated with 
different colors), for males (solid lines) or females (dashed lines). WHAS contains only women and age started at 66, while 
InCHIANTI and BLSA had a small fraction of younger patients and both sexes.
 
Figure A.4. Trajectory of calcium values with age estimated for different age groups. Yearly change in calcium (left panel) and 
albumin-adjusted calcium (alb-adj. ca; right panel) are plotted as a function of age. Trajectories were estimated using Bayesian mixed 
models with age as a cubic spline (with 3 knots) for three longitudinal cohorts (as indicated with different colors), and for different age 
subsets: younger than 65 years old (dashed lines), 65 to 80 years old (dotted lines), and older than 80 years old (dot-dash lines). 
Analyses for WHAS were performed either combining WHAS I and WHAS II (red), or with either one (darker red for WHAS I and 
lighter red for WHAS II). Age started at 66 for WHAS, while InCHIANTI and BLSA had a small fraction of younger patients.
Figure A.5. Trajectory of absolute calcium values with age estimated for different age groups. Yearly change in absolute 
calcium (|calcium|; left panel) and absolute albumin-adjusted calcium (|alb-adj. ca|; right panel) are plotted as a function of age. 
Trajectories were estimated using Bayesian mixed models with age as a cubic spline (with 3 knots) for three longitudinal cohorts (as 
indicated with different colors), and for different age subsets: younger than 65 years old (dashed lines), 65 to 80 years old (dotted 
lines), and older than 80 years old (dot-dash lines). Analyses for WHAS were performed either combining WHAS I and WHAS II 
(red), or with either one (darker red for WHAS I and lighter red for WHAS II). Age started at 66 for WHAS, while InCHIANTI and 
BLSA had a small fraction of younger patients.
Figure A.6. Trajectory of absolute calcium values with age.  Yearly change in absolute calcium (|calcium|; left panel) and absolute 
albumin-adjusted calcium (|alb-adj. ca|; right panel) are plotted as a function of age. Trajectories were estimated using Bayesian 
mixed models with age as a cubic spline (with 5 knots for InCHIANTI and BLSA, and 4 knots for WHAS) for three longitudinal 
cohorts, as indicated with different colors, using centered and reduced variables. Analyses for WHAS were performed either 
combining WHAS I and WHAS II (solid lines), or with either one (dashed and dotted lines, respectively for WHAS I and WHAS II). 
Age started at 66 for WHAS, while InCHIANTI and BLSA had a small fraction of younger patients.
Figure A.7. Yearly changes in absolute calcium values with age. Yearly change in absolute calcium (|calcium|; left panel) and 
absolute albumin-adjusted calcium (|alb-adj. ca|; right panel) were estimated using Bayesian linear mixed models using centered and 
reduced variables, and slopes (points) obtained are plotted with their 95% confidence intervals. Different colors indicate different 
datasets and text on the right describe the cohort subset on which the analysis was performed. Analyses for WHAS were performed 
either combining WHAS I and WHAS II (solid lines), or with either one (dashed and dotted lines, respectively for WHAS I and 
WHAS II). Result for heterogeneity test are also indicated. Significant results are plotted in bold, with asterisks indicating the 
significance level (***, p < 0.001; **, p < 0.01; *, p < 0.05).
Figure A.8. Relationships between absolute calcium values and mortality. Estimated hazard ratios (points) together with 95% CIs 
(segments) are plotted for absolute calcium (|calcium|; left panel) and absolute albumin-adjusted calcium (|alb-adj. ca|; right panel), 
based on counting process Cox proportional hazards models with centered and reduced variables. See Fig. A.7 for further 
explanations.
Figure A.9. Relationships between absolute calcium values and frailty. Poisson regression models were performed on the number 
of Fried’s frailty criteria (Fried and others 2001) for absolute calcium (|calcium|; left panel) and absolute albumin-adjusted calcium 
(|alb-adj. ca|; right panel), adjusting for age and using centered and reduced variables. Estimations (points) together with 95% CIs 
(segments) are plotted. Longitudinal analyses are shown on the top panels (for WHAS only) and cross-sectional analyses (using the 
number of frailty criteria at first visit only) are presented on the lower panels. See Fig. A.7 for further explanations.
Figure A.10. Relationships between calcium values and frailty using ordered logistic regression. Ordered logistic regression 
models were performed on the number of Fried’s frailty criteria at first visit (Fried and others 2001) for unadjusted calcium left panel) 
and albumin-adjusted calcium (alb-adj. ca; right panel), adjusting for age and using centered and reduced variables. Estimations 
(points) together with 95% CIs (segments) are plotted. See Fig. A.7 for further explanations.
